Home > Resources > Company Profiles > Trimeris, Incorporated

Trimeris, Incorporated (TRMS)

EMAIL
PRINT
SHARE
TEXT SIZE:
SHARE
Send a copy to me

Separate multiple email addresses (max 20) with commas.

0/1500
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME


Overview
News
People
Financials

Company Information

Dr. Martin A. Mattingly, Pharm.D., Director/CEO/President

2530 Meridian Parkway

2nd Floor

Durham, NC 27713

US Map it

Phone: (919) 806-4682

Fax: (919) 419-1816

www.trimeris.com



Overview

A biopharmaceutical company, which is engaged in the commercialization of a class of antiviral drug treatments called fusion inhibitors.

Employees

Number of Employees: 9
Revenue per Employee: $576,922

Top Executives

Andrew L. Graham, C.P.A., Secretary/CFO/Other Corporate Officer
Dr. Michael A. Alrutz, J.D., Ph.D., General Counsel
Dr. Carol Ohmstede, Ph.D., Vice President, Divisional

Board of Directors

Joseph P. Healy, Director
Andrew L. Graham, C.P.A., Secretary/CFO/Other Corporate Officer
Stephen R. Davis, Director

Financials

Quarterly
Annual

Income Statement 09/2008 06/2008 03/2008 12/2007
Sales -43 K. -56 K. -83 K. -212 K.
Gross Operating Profit 4.79 Mil. 5.64 Mil. 12.54 Mil. 10.59 Mil.
Operating Income before D & A (EBITDA) 871 K. 2.23 Mil. 8.58 Mil. 5.11 Mil.
Total Income Before Interest Expenses (EBIT) 491 K. 2.68 Mil. 9.31 Mil. 5.71 Mil.
Total Net Income 590 K. 2.33 Mil. 9.06 Mil. 5.54 Mil.
Basic EPS, Total 0.03 0.11 0.41 0.25
Diluted EPS, Total 0.03 0.1 0.41 0.25

BALANCE STATEMENT 09/2008 06/2008 03/2008 12/2007
Cash and Equivalents 21.7 Mil. 37.51 Mil. 32.7 Mil. 43.25 Mil.
Total Assets 38.78 Mil. 69.48 Mil. 73.62 Mil. 68.44 Mil.
Total Liabilities 5.25 Mil. 4.6 Mil. 6.44 Mil. 6.33 Mil.
Total Capitalization 37.83 Mil. 70.24 Mil. 67.32 Mil. 59.03 Mil.

Cash Flow 09/2008 06/2008 03/2008 12/2007
Net Cash From Continuing Operations 12.65 Mil. 9.41 Mil. 21.59 Mil. 15.1 Mil.
Net Cash From Investing Activities 9.68 Mil. -4.61 Mil. -19.12 Mil. -2.05 Mil.
Net Cash From Financing Activities -33.33 Mil. 0 173 K. 152 K.
Net Change in Cash & Cash Equivalents -11 Mil. 4.8 Mil. 2.65 Mil. 13.2 Mil.

powered by Interactive Data

Income Statement 2008 2007 2006 2005
Sales 8.46 Mil. 2.3 Mil. 595 K. 748 K.
Gross Operating Profit 40.92 Mil. 12.94 Mil. 9.91 Mil. 5.96 Mil.
Operating Income before D & A (EBITDA) 16.94 Mil. -17.85 Mil. -17.8 Mil. -25.5 Mil.
Total Income Before Interest Expenses (EBIT) 28.44 Mil. 8.19 Mil. -7.36 Mil. -39.93 Mil.
Total Net Income 27.42 Mil. 7.38 Mil. -8.11 Mil. -40.09 Mil.
Basic EPS, Total 1.24 0.34 -0.37 -1.86
Diluted EPS, Total 1.24 0.34 -0.37 -1.86

BALANCE STATEMENT 2008 2007 2006 2005
Cash and Equivalents 32.7 Mil. 30.05 Mil. 23.56 Mil. 28.1 Mil.
Total Assets 73.62 Mil. 62.48 Mil. 48.81 Mil. 56.05 Mil.
Total Liabilities 6.44 Mil. 8.91 Mil. 8.08 Mil. 6.85 Mil.
Total Capitalization 67.32 Mil. 37.77 Mil. 24.37 Mil. 30.35 Mil.

Cash Flow 2008 2007 2006 2005
Net Cash From Continuing Operations 21.59 Mil. 12.18 Mil. -10.03 Mil. -42.63 Mil.
Net Cash From Investing Activities -19.12 Mil. -6.15 Mil. 4.87 Mil. 25.03 Mil.
Net Cash From Financing Activities 173 K. 468 K. 619 K. 411 K.
Net Change in Cash & Cash Equivalents 2.65 Mil. 6.49 Mil. -4.54 Mil. -17.18 Mil.

powered by Interactive Data







Related Companies by Market Cap
Company Name
Price
Change
Market Cap
Cell Genesys, Inc.
149.87 Mil.
Vical, Incorporated
147.37 Mil.
ImmunoGen, Incorporated
146.24 Mil.
Targacept, Incorporated
145.36 Mil.

Company Profile Change Request

The data provided in our company profiles comes from third party information providers.

Also in Portfolio.com
Most Read
Most Emailed
Recently Commented